Rodolphe Clerval

Company: Coave Therapeutics

Job title: CEO

Seminars:

AAV-ligand Conjugates, a New Capsid Platform For Improved Gene Therapy Delivery 12:00 pm

AAV capsids from 1st and last generations limitations (efficiency and safety) are related to the nature of the capsid composition Chemical conjugation of AAV capsid alter dramatically the biology of AAV leading to improve bio distribution, transduction and immunological profile Chemical conjugation of AAV is a versatile and scalable new capsid technologyRead more

day: Track A - Day 1 AM